Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cea.14305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Televisits for patients with atopic dermatitis treated with dupilumab: experience from a tertiary care center in Northern Italy.
Ital J Dermatol Venerol
December 2024
Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy.
Background: Atopic dermatitis (AD) is an inflammatory skin disease. The monoclonal antibody dupilumab can provide a rapid response with achievement of stable clinical disease. This study aimed to confirm the effectiveness of a televisit approach for patients with AD and treated with dupilumab.
View Article and Find Full Text PDFSwitching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study.
J Allergy Clin Immunol Pract
December 2024
Department of Dermatology, University Hospital of Nice, Côte d'Azur University, Nice, France. Electronic address:
Background: Patients with atopic dermatitis (AD) may discontinue dupilumab owing to dupilumab-induced ocular adverse events (DOAEs) or dupilumab-induced facial redness (DFR).
Objective: To evaluate DOAE and DFR outcomes after switching to tralokinumab or Janus kinase inhibitor (JAKi).
Methods: This retrospective study included 106 patients discontinuing dupilumab because of DOAEs and/or DFR.
Possible Biological Heterogeneity of Airway Mucus Plugs in a Patient with Asthma.
J Asthma Allergy
December 2024
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Saga Prefecture, Japan.
Background: The presence of mucus plugs in the airway is a severe phenotype in patients with asthma; however, the mechanisms and specific treatments are not fully understood.
Purpose: To clarify the efficacy of biologics and the mechanisms for mucus plug in patients with asthma.
Patients And Methods: A 79-year-old Japanese asthmatic woman with high blood eosinophil and fractional exhaled nitric oxide (FeNO) was pointed massive mucus plugs in airway on chest CT imaging.
Monoclonal Antibody Switching in Biologic Treatment of Chronic Rhinosinusitis with Nasal Polyps.
J Clin Med
November 2024
Department of Otorhinolaryngology, Medical University of Graz, 8010 Graz, Austria.
to evaluate our real-world data on the efficacy and safety of switching between two monoclonal antibodies in biologic treatment of uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). All patients receiving biologic treatment for uncontrolled CRSwNP between April 2020 and March 2024 at a tertiary referral center who needed transitioning between biologic agents were retrospectively analyzed. The following parameters were investigated: patient's clinical characteristics, wash-out periods, treatment outcome, and switching-related side effects.
View Article and Find Full Text PDFSwitching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience.
Int Forum Allergy Rhinol
October 2024
Division of Otolaryngology-Head & Neck Surgery, University of British Columbia, Vancouver, Canada.
Background: Type 2 biologics have been used increasingly for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). However, patterns of biologic switching are understudied, and established guidelines for sequential or simultaneous use do not yet exist.
Methods: This is a Canadian multicenter retrospective study of real-world patient data.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!